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use antibiotics reasonably has become an urgent problem
to be solved. 
OBJECTIVE: The purpose of this study was to evaluate
the efficacy and cost of ceftriaxone, cefotaxime, and ce-
furoxime therapy in patients with moderate lower respi-
ratory tract infection. 
METHODS: 150 patients with moderate lower respira-
tory tract infection were randomized to receive ceftriax-
one (1g .d), cefotaxime (1g b.i.d), and cefuroxime (0.75g
t.i.d). Evaluation of clinical efficacy depended on
whether or not clinical findings subsiding eradication of
the initially susceptible and normal outcome of labora-
tory tests were obtained 7 days after therapy. In the cost
analysis we have taken the following costs into account:
drug cost, check-up cost, bed cost, administration cost,
treatment of adverse events, and lost income of patients. 
RESULTS: 107 patients were analyzed. The effectiveness
rates of ceftriaxone, cefotaxime, and cefuroxime arms
are 86.21 (25/29), 85.37 (35/41), and 75.68% (31/38),
respectively, with no significant difference (p  0.05),
but their costs are 2931.97  161.84, 3749.52 
215.98, and 3340.56  221.26 yuan (RMB), respec-
tively, with significant difference (p  0.05).
CONCLUSION: Our pharmacoeconomic analysis dem-
onstrated that of all the three drugs ceftriaxone had the
best cost-effectiveness, and was a better choice for the
treatment of moderate lower respiratory tract infection.
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OBJECTIVE: A prevention effectiveness analysis frame-
work was used to estimate the cost-effectiveness of a tu-
berculosis prevention program compared to no program
along the US/Mexico border. The prevention program
used prophylactic isoniazid therapy in patients who
tested positive for tuberculosis infection. This analysis
evaluated the cost-effectiveness of the tuberculosis pre-
vention from the county government perspective and was
modeled over two time periods, 5 and 15 years post-pre-
ventive therapy initiation. 
METHODS: The outcome of interest, cases of active tu-
berculosis averted, was calculated through a Monte Carlo
simulated Markov process model. Costs were calculated
using hospital discharge and actual tuberculosis preven-
tion and active treatment program data. Average and in-
cremental cost-effectiveness ratios were calculated for the
tuberculosis prevention program scenario. Cost-effective-
ness ratios were calculated separately with the inclusion
or exclusion of the tuberculosis contagion costs. 
RESULTS: The results indicate that the tuberculosis pre-
vention program provides cost-savings to the county.
Baseline incremental cost-effectiveness ratios, for the 5
and 15 year analyses, demonstrated substantial cost sav-
ings ($1023 and $4971 per case averted, respec-
tively). Sensitivity analyses were performed across key
transitional probabilities and discount rates. Results of
sensitivity analyses indicate that as the rate of hospital-
ization for tuberculosis decreased and compliance with
the preventive therapy decreased, cost-effectiveness ratios
increased to $2015 and $877 per case averted, respec-
tively, for the 5-year preventive treatment scenario. How-
ever, when the tuberculosis contagion consequences of
not having the tuberculosis prevention program were
considered, the cost-effectiveness and cost-savings were
once again realized. 
CONCLUSION: The results indicate that rather than in-
curring costs to avert active tuberculosis cases, having the
tuberculosis prevention program results in cost-savings.
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Influenza is a common disease that is often perceived as
self-limiting and mainly treated at home. However, for a
portion of influenza sufferers the disease may warrant a
visit to the emergency room (ER) or hospitalization. 
OBJECTIVE: The purpose of this study is to estimate the
resources consumed and associated costs of treating in-
fluenza patients in the ER and hospital. 
METHODS: Patient-level clinic and cost data were mea-
sured for the study population identified in the Premier
Decision Support Services (DSS) databases. Data were
analyzed retrospectively from January 1, 1997 to June
30, 1998 for patients with a diagnosis code for influenza
using International Classification of Diseases, Ninth Re-
vision-Clinical Modification (ICD-9) coding. Individual
medication data were collected for a subset of the sub-
jects in 1997 and all subjects in 1998. Data were summa-
rized using means (SE) and multivariate analyses of
variance (  0.05) were performed to determine if ob-
served differences in mean costs across demographic vari-
ables were statistically significant. 
RESULTS: Of the 1362 patients who met inclusion crite-
ria, 333 (24.4%) required an inpatient hospital stay for
influenza. The average total cost and charge per patient
for ER only visits were approximately $142 and $218,
respectively. The average total cost and charge per hospi-
talized patient were approximately $3251 and $5938, re-
spectively. Other cost and demographic data are further
detailed in the study. 
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CONCLUSION: Influenza is not a benign disease. For
some infected patients, ER or hospital care is needed.
More aggressive and effective prevention and treatment
strategies may lead to cost avoidance via fewer influenza
related ER visits and hospitalizations.
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OBJECTIVE: Treatment for acute exacerbation of chronic
bronchitis (AECB) frequently consists of antimicrobial
therapy. The persistence of recurrent symptoms can lead
to substantial morbidity and increased healthcare costs.
These factors make it important to consider antimicro-
bial treatment from an economic as well as a clinical per-
spective. This study was designed to assess the relative ef-
fectiveness and cost of once-daily clarithromycin (CL
OD) 500 mg versus amoxycillin/clavulanic acid (AMCL)
625 mg TID in the treatment of AECB. 
METHODS: Of 250 patients enrolled in this investigator-
blind, multicenter, multicountry comparative trial of CL
OD and AMCL in adults with AECB, 127 were random-
ized to treatment with CL OD, and 123 with AMCL. The
primary measure of clinical effectiveness was response to
therapy. Healthcare resource utilization was monitored
from initiation of therapy to 19–23 days after the last study
medication. UK costs were applied to resource use aggre-
gated across all countries in the base case analysis. 
RESULTS: Investigator-defined clinical response rates
were similar in the clinically evaluable population (93/
106 [88%] CL OD and 85/99 [86%] AMCL, p  0.837).
Mean per patient costs were CL OD £120 (95% CI 6–234)
and AMCL £146 (95% CI 5–287). Mean length of stay
for hospitalized patients was 10.80 days for CL OD ver-
sus 15.25 days for AMCL. Both hospitalization costs and
study medication costs were lower for CL OD.
CONCLUSIONS: Previous studies have shown favorable
cost comparisons for CL OD versus AMCL but these
have been based on decision models. Results from this
study provide the first evidence of a trend of cost savings
for CL OD versus AMCL from a prospective random-
ized, multicountry trial.
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OBJECTIVE: Cystic fibrosis is a genetic disease in which
respiratory infections, usually due to Pseudomonas, are
the major cause of morbidity and mortality. A 20-week
double-blind placebo (P) controlled trial conducted in the
United States has shown that a new formulation of To-
bramycin (T) designed for jet nebulization and better tol-
erability produces significant improvements in pulmo-
nary function tests, as well as decreases in the concentra-
tions of Pseudomonas aeruginosa in sputum and a 26%
(95% CI 2–43%) decrease in the probability of being
hospitalized (Ramsey et al. NEJM 340:1;23–30, 1999). 
METHODS: Individual patient-data from the trial were
used to calculate the average number of days spent in
hospital, on home intravenous (IV) and oral antibiotic
therapy. Separate calculations were performed for the
subgroups of patients with FEV1 	50% of predicted and
FEV1 50% of predicted. To adjust for Canadian pric-
ing, pertinent economic parameters were obtained from
the Ontario and Quebec Ministries of Health. Usual care
data were obtained from a Delphi panel composed of the
medical directors of the cystic fibrosis clinics. 
RESULTS: Pertinent pharmacoeconomic results reported
in days and 95% CI were as follows: In hospital: T 
5.2, P  8.2; Dif  3 (5.02 to 0.97). Home IV ther-
apy: T  5.9, P  10.1; Dif.  3.1 (6.25 to 1.03).
Home oral therapy: T  15.4, P  18.1; Dif  2.7
(6.52 to 1.07). The average savings in direct medical
costs that could be produced by the use of T during a 20-
week treatment period in Quebec and Ontario would
amount to $10,802 per patient. A maximal saving of
$22,735 would be obtained in Ontario children with
FEV1 50% of predicted. A minimal saving of $4869
would correspond to Quebec adults with FEV1 50% of
predicted. 
CONCLUSIONS: Substantial savings in direct medical
costs could be obtained by using inhaled T to decrease
the rate of recurrent pulmonary infections in patients
with cystic fibrosis.
ECONOMIC AND OUTCOMES ISSUES OF 
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NSAIDs are considered minor drugs in that their clinical
benefit is limited to reduction of symptoms. Although
they may be responsible for about 25% of side effects,
some of them fatal, most NSAIDs are prescribed for con-
troversial indications. An intervention was prospectively
